3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
CNS
1
Conditions
Carcinoma, Non-Small-Cell Lung
4
Sarcoma
2
Neoplasm Metastasis
2
Thyroid Neoplasms
1
Thyroid Diseases
1
Thoracic Neoplasms
1
Solitary Fibrous Tumors
1
Respiratory Tract Neoplasms
1
Respiratory Tract Diseases
1
Neuroendocrine Tumors
1
Neuroectodermal Tumors
1
Neoplasms, Germ Cell and Embryonal
1
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Neoplasms
1
Lymphoma, Large-Cell, Anaplastic
1
Lymphoma
1
Lung Neoplasms
1
Lung Diseases
1
Intestinal Neoplasms
1
Intestinal Diseases
1
Head and Neck Neoplasms
1
Granuloma, Plasma Cell
1
Glioma
1
Glioblastoma
1
Gastrointestinal Neoplasms
1
Gastrointestinal Diseases
1
Endocrine System Diseases
1
Endocrine Gland Neoplasms
1
Digestive System Neoplasms
1
Interventions
Magnetic Resonance Spectroscopy
23
Radiosurgery
21
Temozolomide
14
Bevacizumab
12
pembrolizumab
10
Specimen Handling
9
Nivolumab
8
Radiotherapy
7
Ipilimumab
7
Magnetic Resonance Imaging
6
Cyclophosphamide
5
Capecitabine
5
Blood Specimen Collection
5
encorafenib
4
Radiation
4
Neuropsychological Tests
4
Mental Status and Dementia Tests
4
Memantine
4
Carboplatin
4
fludarabine
3
fluciclovine F-18
3
binimetinib
3
abemaciclib
3
Watchful Waiting
3
Proton Therapy
3
Etoposide
3
Dexamethasone
3
Adrenal Cortex Hormones
3
trastuzumab deruxtecan
2
sacituzumab govitecan
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Brain Neoplasms
×
repotrectinib
×
Clear all
NCT06315010
2026-02-25
REPOSE
MedSIR
Phase 2
Recruiting
20 enrolled